102 related articles for article (PubMed ID: 22248302)
1. From the first selective non-peptide AT(2) receptor agonist to structurally related antagonists.
Murugaiah AM; Wu X; Wallinder C; Mahalingam AK; Wan Y; Sköld C; Botros M; Guimond MO; Joshi A; Nyberg F; Gallo-Payet N; Hallberg A; Alterman M
J Med Chem; 2012 Mar; 55(5):2265-78. PubMed ID: 22248302
[TBL] [Abstract][Full Text] [Related]
2. Comparative functional properties of two structurally similar selective nonpeptide drug-like ligands for the angiotensin II type-2 (AT(2)) receptor. Effects on neurite outgrowth in NG108-15 cells.
Guimond MO; Wallinder C; Alterman M; Hallberg A; Gallo-Payet N
Eur J Pharmacol; 2013 Jan; 699(1-3):160-71. PubMed ID: 23211679
[TBL] [Abstract][Full Text] [Related]
3. Selective angiotensin II AT2 receptor agonists: arylbenzylimidazole structure-activity relationships.
Wu X; Wan Y; Mahalingam AK; Murugaiah AM; Plouffe B; Botros M; Karlén A; Hallberg M; Gallo-Payet N; Alterman M
J Med Chem; 2006 Nov; 49(24):7160-8. PubMed ID: 17125268
[TBL] [Abstract][Full Text] [Related]
4. Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition.
Mahalingam AK; Wan Y; Murugaiah AM; Wallinder C; Wu X; Plouffe B; Botros M; Nyberg F; Hallberg A; Gallo-Payet N; Alterman M
Bioorg Med Chem; 2010 Jun; 18(12):4570-90. PubMed ID: 20493713
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist.
Wan Y; Wallinder C; Plouffe B; Beaudry H; Mahalingam AK; Wu X; Johansson B; Holm M; Botoros M; Karlén A; Pettersson A; Nyberg F; Fändriks L; Gallo-Payet N; Hallberg A; Alterman M
J Med Chem; 2004 Nov; 47(24):5995-6008. PubMed ID: 15537354
[TBL] [Abstract][Full Text] [Related]
6. Selective angiotensin II AT(2) receptor agonists devoid of the imidazole ring system.
Murugaiah AM; Wallinder C; Mahalingam AK; Wu X; Wan Y; Plouffe B; Botros M; Karlén A; Hallberg M; Gallo-Payet N; Alterman M
Bioorg Med Chem; 2007 Nov; 15(22):7166-83. PubMed ID: 17825570
[TBL] [Abstract][Full Text] [Related]
7. New selective AT2 receptor ligands encompassing a gamma-turn mimetic replacing the amino acid residues 4-5 of angiotensin II act as agonists.
Rosenström U; Sköld C; Plouffe B; Beaudry H; Lindeberg G; Botros M; Nyberg F; Wolf G; Karlén A; Gallo-Payet N; Hallberg A
J Med Chem; 2005 Jun; 48(12):4009-24. PubMed ID: 15943474
[TBL] [Abstract][Full Text] [Related]
8. First reported nonpeptide AT1 receptor agonist (L-162,313) acts as an AT2 receptor agonist in vivo.
Wan Y; Wallinder C; Johansson B; Holm M; Mahalingam AK; Wu X; Botros M; Karlén A; Pettersson A; Nyberg F; Fändriks L; Hallberg A; Alterman M
J Med Chem; 2004 Mar; 47(6):1536-46. PubMed ID: 14998339
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II pseudopeptides containing 1,3,5-trisubstituted benzene scaffolds with high AT2 receptor affinity.
Georgsson J; Sköld C; Plouffe B; Lindeberg G; Botros M; Larhed M; Nyberg F; Gallo-Payet N; Gogoll A; Karlén A; Hallberg A
J Med Chem; 2005 Oct; 48(21):6620-31. PubMed ID: 16220978
[TBL] [Abstract][Full Text] [Related]
10. A selective AT2 receptor ligand with a gamma-turn-like mimetic replacing the amino acid residues 4-5 of angiotensin II.
Rosenström U; Sköld C; Lindeberg G; Botros M; Nyberg F; Karlén A; Hallberg A
J Med Chem; 2004 Feb; 47(4):859-70. PubMed ID: 14761188
[TBL] [Abstract][Full Text] [Related]
11. Development of selective non-peptide angiotensin II type 2 receptor agonists.
Alterman M
J Renin Angiotensin Aldosterone Syst; 2010 Mar; 11(1):57-66. PubMed ID: 19880657
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of a new class of druglike angiotensin II C-terminal mimics with affinity for the AT2 receptor.
Georgsson J; Sköld C; Botros M; Lindeberg G; Nyberg F; Karlén A; Hallberg A; Larhed M
J Med Chem; 2007 Apr; 50(7):1711-5. PubMed ID: 17358051
[TBL] [Abstract][Full Text] [Related]
13. N-(Methyloxycarbonyl)thiophene sulfonamides as high affinity AT2 receptor ligands.
Wannberg J; Gising J; Lindman J; Salander J; Gutiérrez-de-Terán H; Ablahad H; Hamid S; Grönbladh A; Spizzo I; Gaspari TA; Widdop RE; Hallberg A; Backlund M; Leśniak A; Hallberg M; Larhed M
Bioorg Med Chem; 2021 Jan; 29():115859. PubMed ID: 33309749
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin Peptides as AT2 Receptor Agonists.
Hallberg M; Sävmarker J; Hallberg A
Curr Protein Pept Sci; 2017; 18(8):809-818. PubMed ID: 28164758
[TBL] [Abstract][Full Text] [Related]
15. Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships.
Wallinder C; Botros M; Rosenström U; Guimond MO; Beaudry H; Nyberg F; Gallo-Payet N; Hallberg A; Alterman M
Bioorg Med Chem; 2008 Jul; 16(14):6841-9. PubMed ID: 18599297
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of 1,2,4-triazole bearing 5-substituted biphenyl-2-sulfonamide derivatives as potential antihypertensive candidates.
Liu J; Liu Q; Yang X; Xu S; Zhang H; Bai R; Yao H; Jiang J; Shen M; Wu X; Xu J
Bioorg Med Chem; 2013 Dec; 21(24):7742-51. PubMed ID: 24200932
[TBL] [Abstract][Full Text] [Related]
17. Selenosartans: novel selenophene analogues of milfasartan and eprosartan.
Grange RL; Ziogas J; North AJ; Angus JA; Schiesser CH
Bioorg Med Chem Lett; 2008 Feb; 18(3):1241-4. PubMed ID: 18191398
[TBL] [Abstract][Full Text] [Related]
18. 2,3-Dihydro-2-oxo-1H-benzimidazole-1-carboxamides with selective affinity for the 5-HT(4) receptor: synthesis and structure-affinity and structure-activity relationships of a new series of partial agonist and antagonist derivatives.
Tapia I; Alonso-Cires L; López-Tudanca PL; Mosquera R; Labeaga L; Innerárity A; Orjales A
J Med Chem; 1999 Jul; 42(15):2870-80. PubMed ID: 10425096
[TBL] [Abstract][Full Text] [Related]
19. N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
Menghin S; Pertz HH; Kramer K; Seifert R; Schunack W; Elz S
J Med Chem; 2003 Dec; 46(25):5458-70. PubMed ID: 14640554
[TBL] [Abstract][Full Text] [Related]
20. Novel carbamates as potent histamine H3 receptor antagonists with high in vitro and oral in vivo activity.
Stark H; Purand K; Ligneau X; Rouleau A; Arrang JM; Garbarg M; Schwartz JC; Schunack W
J Med Chem; 1996 Mar; 39(5):1157-63. PubMed ID: 8676353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
